A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma in the United Kingdom (UK)
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ipsen
- 23 Aug 2019 Status changed from recruiting to completed.
- 26 Jun 2019 Planned End Date changed from 31 May 2019 to 30 Sep 2019.
- 26 Jun 2019 Planned primary completion date changed from 31 May 2019 to 30 Sep 2019.